UBI is headquartered in Hauppauge, NY with operational divisions in Taipei and Hsin-Chu, Taiwan and Shanghai and Beijing, China.
UBI is headquartered in 45,000 SF building in Hauppauge, NY. An FDA establishment license was obtained for this facility in 1994 for the manufacture of biologics, and the USDA approved this facility for manufacture of animal biologics in 2004. We further renovated and equipped additional research and development facilities in Hauppauge for the manufacture, under GMP, of various peptides in larger scales for use in our proprietary products and vaccines for clinical trials and regulatory filing purposes.
UBI’s China operations are located in 168,000 SF in Shanghai’s premier ZhiZhu Science Park. The new UBI-China base includes facilities for the manufacture of API peptides, for manufacturing human and animal vaccines and diagnostics, and for R&D support activities. This facility was approved by the Ministry of Agriculture, PRC for GMP compliance in 2007.
UBI’s diagnostic kit manufacturing facility is located Shanghai’s Zhang Jiang Science Park. This facility was approved for ISO 13485 certification for the production of UBI HCV test as required for CE marking, the first manufacturer of a blood screening test in China to have received such recognition and certification.
UBI also has an administrative office in Beijing, China.
Through its joint venture in Taiwan (UBI-Asia), UBI acquired a pharmaceutical plant from Roche with 203,000 SF of land and 91,000 SF of multistory manufacturing facilities in Hsin-Chu, the high-tech capital of Taiwan. This facility was certified by the Ministry of Health, Republic of China (ROC, Taiwan) in 1999 for UBI-Asia to manufacture human pharmaceuticals in multiple formulations, under contracts, for sales in ROC (Taiwan) and certain regional markets.
UBI-Asia acquired a second pharmaceutical plant in Hsin-Chu from GlaxoSmithKline with 240,000 SF of land and 98,000 SF of multistory manufacturing facilities. This acquisition allowed for the consolidation of UBI-Asia’s manufacturing and R&D operations to two neighboring sites. UBI-Asia also established a pilot scale peptide manufacturing plant and pilot plant for manufacture of CHO cell-derived monoclonal antibody for clinical trials. Both were fully validated in 2004. In 2007, this facility was approved by the Department of Health, ROC as cGMP compliant and approved for the production of clinical grade humanized monoclonal antibodies.
UBI-Asia also has an administrative headquarters in Taipei 101 building in Taipei, China.